Traitement combiné d'insuline et d'analogue du GLP-1: qu'en attendre [Combined treatment of insulin and GLP-1 analogs: what do we expect?].

Détails

ID Serval
serval:BIB_698E4ADC87DC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Traitement combiné d'insuline et d'analogue du GLP-1: qu'en attendre [Combined treatment of insulin and GLP-1 analogs: what do we expect?].
Périodique
Revue Médicale Suisse
Auteur(s)
de Kalbermatten B., Jaafar J., Jornayvaz F.R., Philippe J.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2014
Volume
10
Numéro
433
Pages
1235-6, 1238-40
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review Publication Status: ppublish
Résumé
Type 2 diabetes mellitus is a progressive and heterogeneous disease. The decrease in insulin secretion by pancreatic beta cells and the increase of glucagon secretion by pancreatic beta cells, are the two major pathophysiologic characteristics. The majority of type 2 diabetics will therefore require insulin in the evolution of their disease, with weight gain and hypoglycaemia as side effects. GLP-1 analogs are effective therapeutic alternatives due to their actions on glucagon and insulin secretion, on satiety and gastric emptying. For patients inadequately controlled with conventional antidiabetics, GLP-1 analogs, introduced as an alternative or in combination with insulin, can prevent or reduce the side effects associated with insulin. Indeed, the risk of hypoglycaemia is reduced and the vicious circle of weight gain secondary to insulin/need to increase insulin doses is limited.
Mots-clé
Diabetes Mellitus, Type 2/drug therapy, Diabetes Mellitus, Type 2/etiology, Drug Therapy, Combination, Glucagon-Like Peptide 1/analogs & derivatives, Humans, Hypoglycemic Agents/administration & dosage, Incretins/administration & dosage, Insulin/administration & dosage, Molecular Targeted Therapy
Pubmed
Création de la notice
10/09/2015 12:59
Dernière modification de la notice
20/08/2019 15:24
Données d'usage